Vancomycin HCL Capsules for treatment for C. difficile-Associated Diarrhea (CDAD) Launched by ANI Pharmaceuticals,Inc.


ANI Pharmaceuticals, Inc.  today announced the launch of Vancomycin HCl 125mg and 250mg capsules indicated for treatment of C. difficile-associated diarrhea.

The overall US market for Vancomycin HCl Capsules is approximately $113 million, per IMS Health.


Arthur S. Przybyl, President and Chief Executive Officer said, “We are pleased to announce the launch of our authorized generic to Vancocin, which replaces the authorized generic previously on the market. This is the second of four generic products we plan to launch before the end of 2015, having previously announced the launch of Oxycodone Oral Solution in October. The launch of an authorized generic for one of our acquired branded products represents an important value driver for ANI and a key component of our mature brand strategy.”

About Vancomycin HCl Capsules

Vancomycin Hydrochloride Capsules are indicated for the treatment of C. difficile-associated diarrhea (CDAD).

Vancomycin Hydrochloride Capsules are also used for the treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains). Parenteral administration of vancomycin is not effective for the above infections; therefore, Vancomycin Hydrochloride Capsules must be given orally for these infections.

About ANI

ANI Pharmaceuticals, Inc. (the “Company” or “ANI”) is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company’s targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products.


To read the article in its entirety click on the link below: